Stelis is committed to making biological treatments accessible to patients globally.

Our products are targeted against large treatment markets that are currently underserved.


Our hybrid operating model combines differentiated bio-similar, novel biologics and authorized manufacture and marketing of in-licensed biologics. With R&D and cGMP manufacturing out of Bangalore, India we aim to bring world-class treatments at affordable costs to patients in Emerging and Developed countries.
Social Responsibility
Corporate
 
Close
 
    At STELIS our operating principles mirror that of our parent company STRIDES:
  • “Making Decisive Moves That Drive Value” – We foresee emerging trends and successfully execute strategies that deliver on stakeholder expectations.
  • “We Provide a Rewarding and Engaging Work Environment” – We encourage an entrepreneurial work culture that fosters creativity and innovation.
  • “Creating Wealth for Shareholders” – Our pioneering initiatives have delivered consistently for our shareholders
  • “Building Value thru Partnerships” - Our partnership philosophy has helped deliver incremental value to both our company and partners
Close
 
    To fulfill our Mission and Vision, we have a state-of-art R&D and are building a manufacturing infrastructure underpinned by a strong technical foundation to support the three pillars of our business model:
  • Strong partnering activities for in-licensing and out-licensing of products to meet global unmet needs
  • Our Mission is to develop and manufacture affordable bio-therapeutics to address global unmet needs
  • Manufacturing of internal product pipeline & contract development and manufacturing of Drug Substance and Drug Product
Close
 
   

PARTNERING ETHOS

  • Partnering (both technology in-licensing & product out licensing) and Contract Manufacturing activities are identified as crucial to Stelis Biopharma for both risk mitigation by means of adding to internal product pipeline as well for revenue generation.
  • We envision integrated collaborative platform to leverage each organizations’ strengths and to achieve the partnership’s business and strategic objectives. It is imperative that Stelis preserve, protect and enhance relationships with its partners for optimized use of R&D and manufacturing facilities.
  • Other benefits which Stelis could offer potential partners include speed to market, access to cutting edge technology for development and manufacturing of cost competitive products and provide access to newer markets, especially in emerging markets.
  • This partnering philosophy creates shareholder value by bringing potential products to market and generating new revenues and profits for both organizations.
Close
 
Stelis Biopharma Partners with Merck
BIO International Convention 2016
  • We are at BIO International Convention 2017, San Diego, California, USA (June 19 - 22).
Principles
Business Model
News and Events
stelis.com
©2016. All Rights Reserved.
Connect with
Stelis Pharma